ClinicalTrials.Veeva

Menu
D

DelRicht Research | Baton Rouge, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
RPT193
Ritlecitinib
Frexalimab
SAR441344
Mirikizumab
Sofpironium Bromide
Secukinumab
PF-06826647
Tirzepatide

Parent organization

This site is a part of DelRicht Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 30 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized A...

Enrolling
Generalized Anxiety Disorder
Drug: MM120 (LSD D-Tartrate)
Other: Placebo

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Active, not recruiting
Chronic Inducible Urticaria
Drug: Oral EVO756

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Active, not recruiting
Masseter Muscle Prominence
Drug: Placebo
Drug: BOTOX

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling
Multiple Sclerosis
Drug: Activated charcoal
Drug: Cholestyramine

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Enrolling
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Invitation-only
Focal Epilepsy
Drug: BHV-7000
Locations recently updated

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: Placebo
Drug: BHV-7000
Status recently updated

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-Rhod...

Enrolling
Active, not recruiting
Acne Vulgaris
Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel...

Active, not recruiting
Actinic Keratoses
Combination Product: BF-200 ALA and red light LED lamp
Combination Product: Vehicle and red light LED lamp

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: YR001 ointment

Trial sponsors

Incyte logo
Lilly logo
Pfizer logo
B
Biohaven logo
RAPT Therapeutics logo
Sanofi logo
AbbVie logo
Amgen logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems